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Summary.-Ninety-nine patients with advanced breast cancer were randomized to
receive either cyclophosphamide continuously or a combinationofcyclophosphamide,
methotrexate, 5-fluorouracil and vinblastine given intermittently. The number and
duration of objective responses were greater in patients receiving the combination
but the differences between the two treatments did not achieve formal significance.
The combination was logistically easier to manage and produced less toxicity.
IN RECENT years, there have been some
notable advances in the results of cancer
chemotherapy by using drugs in combina-
tion instead of singly (Frei, 1972). Major
improvements have occurred in the treat-
ment of acute lymphoblastic leukaemia
(Henderson, 1969) and some lymphomata,
particularly advanced Hodgkin's disease
(DeVita, Serpick and Carbone, 1970).
The common carcinomata are less re-
sponsive and, in gastrointestinal (Carter
and Friedman, 1974) and ovarian cancer
(Schein, 1973), combinations of drugs are
not superior to single agents. It is now
believed that in advanced breast cancer
combination chemotherapy produces more
remissions which are of longer duration
than those obtained with the agents used
singly. The evidence for this has recently
been reviewed (Broder and Tormey, 1974)
but it has not been formally established
in a controlled trial. Such a study was
started at the Breast Unit, Guy's Hos-
pital in June 1970andtheresults to theend
of December 1974 are noW reported.
PATIENTS AND METHODS
Ninety-nine patients with advanced breast
cancer entered the trial. None had had
previous chemotherapy and all had relapsed
after, or had failed to respond to, previous
endocrine therapy. There were 4 categories
of patients: (1) those who had had a hypo-
physectomy but had failed to respond or had
subsequently relapsed; (2) those considered
too old for hypophysectomy (over 65 years);
(3) those selected as unlikely to benefit from
hypophysectomy because they had had a
period free from disease after excision of the
primary tumour of less than 2 years, or were
less than 6 years post-menopausal, except in
cases where discriminant (Atkins et al., 1968)
was positive; (4) those considered medically
unfit for hypophysectomy.
The patients were randomly allocated to
one of 2 treatment groups, namely cyclo-
phosphamide alone (C) or a regimen of4 drugs
(4D). Group C were treated as had been the
usual practice in this Unit for about 10 years.
They received cyclophosphamide orally at a
daily dose depending on body weight (<48
kg, 200 mg; 48-58 kg, 250 mg; >58 kg, 300
mg). The white blood cell count was esti-
mated weekly and treatment was stopped if
this fell below 2000/41; it was resumed when
it had risen to 3000/,ul.
The selection of the 4 drugs was deter-
mined by the known efficiency of cyclophos-
phamide. 5-fluorouracil, methotrexate and
the vinca-alkaloids in breast cancer (Carter,
1972). Vinblastine was chosen rather than
vincristine (which has been used more often)
in order to avoid neurotoxicity during an
anticipated long period of treatment.
Group 4D received courses oftreatment as
follows:
Day 1 Oral cyclophosphamide 100 mgCHEMOTHERAPY OF ADVANCED BREAST CANCER
Day 8
Day 15
daily started and continued for
14 days.
Intravenous infusion of 300 ml
saline
5-fluorouracil 500 mg' Injected
separately
Methotrexate 25 mg into
infusion
Vinblastine 5 mgJ tubing
Infusion and intravenous drugs as
Day 1
Infusion and intravenous drugs as
Days 1 and 8
Cyclophosphamide stopped
After a 4-week rest period the cycle, start-
ing at Day 1, was repeated. A course was
started only if the white blood cell count was
above 3000/,ul. The second and third infu-
sions (Days 8 and 15) were postponed if the
white blood cell count fell below 2000, when
the cyclophosphamide was also stopped.
In both Groups C and 4D treatment was
continued indefinitely but was stopped if
the diseaseprogressed orifthepatientrelapsed
after a successful response. At the begin-
ning of treatment patients were assessed by
physical examination, chest x-ray andskeletal
survey. All visible and palpable lesions
(including liver enlargement) were measured
and/or photographed. These records pro-
vided a baseline against which to assess the
response to chemotherapy. Group C patients
were seen at 4-weekly intervals while Group
4D patients were assessed one week before
each course of treatment.
Assessment
The following methods of assessment were
used:
Objective re8pon8e.-This means a measur-
able decrease in the size of one or more
evaluable lesions or sclerosis oflytic bone met-
astases not accompanied by concurrent
increase in other lesions nor the appearance
of new lesions. Disappearance of all known
lesions was deemed a "complete remission".
The duration of a response is thetimefrom the
start of chemotherapy to the time of relapse
or the appearance of new lesions. Although
"objective response" as defined in this way
is not believed to be a good index of the
overall benefit from treatment, it is a criterion
frequently used in the literature and has been
used here so that the results described in this
paper can be compared with other published
work.
50
Mean clinical value (MCV).-This method
ofclinical assessment has been previously des-
cribed in detail (Hayward, 1966). Briefly, all
evaluable lesions are compared with baseline
measurements periodically (usually 4-weekly)
during treatment. For a given lesion a score
of1 denotesnochange, 2denotesimprovement
and 0 deterioration; new lesions score 0.
After grouping the lesions into systems, a
score for each system is obtained by dividing
the sum ofthe scores by the number oflesions
and multiplying by 6. The scores for each
system are then averaged to give the mean
clinical value (MCV). The maximum poss-
ible MCV is 12 which means all lesions are in
regression, while an MCV of 6 (which is the
baseline score) indicates no overall change;
values below 6 are obtained when the disease
progresses despite treatment and reach 0
when all lesionshavemeasurablydeteriorated.
A comparison of the responses to different
treatments can be made from the MCV at a
given time from the start of treatment (3
months in this study) or from the total MCV
which is the sum of the MCVs at 4-weekly
intervals for the duration of therapy.
Success rate.-Treatment was considered
successful, intermediate or a failure over a
defined time period (3, 6, 12 and 24 months
in this study) using the criteria ofthe British
Breast Group (1974).
Success means a measurable improvement
of all known lesions persisting at the end of
the defined time period during which no new
lesions should have appeared. Intermediate
includes all responses which do not last the
defined period and those cases in which some
lesions regress while others get worse, or when
lesions remain static. Failure indicates wors-
ening of the disease for the duration of
treatment.
Survival.-Survival from the start of
chemotherapy has been analysed by the life-
table method andbythe method ofCox (1972).
Statistical methods (Armitage, 1971).-
Differences betweenthe C and4D groups were
compared bythe t test for durationofresponse
and MCV; in addition, Willcoxon's rank sum
test was used for MCV. Success rates were
compared using the chi-square test.
RESULTS
Forty-nine patients were randomly
allocated to Group C and 50 to
Group 4D; no patient was excluded from
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the analysis. Although 3 of the 4D
patients died in the short interval between
randomization and before starting chemo-
therapy they were still included in the
analysis. This was done to maintain
strict comparability between the two
groups, particularly because the Group C
patients were able to start treatment
without delay whereas Group 4D usually
waited for a few days for the first course
of intravenous therapy. The character-
istics ofthe two groups with regard to age
(Table I), time from diagnosis to start of
chemotherapy (Table II), previous treat-
ment (Table III) and extent of disease at
the start of chemotherapy (Table IV)
were similar.
All patients have been followed up for
a minimum of 6 months from the start
of chemotherapy. At the time of ana-
lysis only 6 patients were still in remission
in Group C and 5 in Group 4D. Four
patients in each group were alive on
subsequent therapy having failed on,
or relapsed after, chemotherapy. The
remaining 80 patients have died.
Objective responses (Table V)
Therewere more objective responsesin
Group 4D and the duration of these was
longerbut the difference between the two
treatments wasnotstatisticallysignificant.
Theresponse ratesaccording toanatomical
sites are shown in Table IV. Treatment
was most effective against lesions in the
breast, lymph nodes and skin, particularly
in Group 4D. Skeletal lesions appeared
to respond poorly but this is probably due
to the long time needed for sclerosis of
lytic lesions to become detectable on
radiographs. Hepatic metastasesassessed
by liver size regressed in about half of
TABLE I.-Age at Diagnosi?
Years
21-30
31-40
41-50
51-60
61-70
71-80
Numbers of Pati
Group C Grc
1
7
14
15
10
2
TABLE II.-Time from Diagnosis to Start
of Chemotherapy
Months
0-12
13-24
25-60
>60
Numbers of Patients
Group C Group 4D
5 6
14 12
19 21
11 11
TABLE Ill.-Previous Treatment
Numbers of Patients
Group C Group 4D
Surgical excision of
primary tumour
(wide excision,
simple mastectomy
or radical
mastectomy) :
radiotherapy
Oophorectomy
Androgens
Oestrogens
Hypophysectomy or
Adrenalectomy
Prednisone
TABLE IV.-Sites
Response
Breast
Lymph Nodes IE
Skin 14
Skeleton
Lungs
Pleura
Liver E
Ascites 9
Abdominal mass c
Brain
30
15
19
20
28
7
32
15
23
16
30
11
of Involvement and
No. of patients
Group C Group 4D
9/21 (43%)
8/33 (55%)
7/33 (52%)
7/26 (27%)
2/9
1/14
8/14
2/5
0/2
16/23 (70%)
22/33 (67%)
21/32 (66%)
6/21 (29%)
3/5
3/13
5/11
1/4
0/1
* Denominators indicate the number of patients
with involvement of the stated site at the start of
chemotherapy and numerators show the number
with a response at that site.
TABLE V.-Objective Responses
No. of patients
Group C Group 4D
S No. of patients
Objective responses
.ents Complete remissions
)up 4D Duration of response ~up 4D All patients: Mean
0 Median
7 Range
16 Objective responders
16 only: Mean
8 Median
3 Range
49
27 (55%)
2
(months)
3 9
2
0-24
50
31 (62%)
1
5.5 P<0-2
3
0-30
7-1 8.8 P<0.3
5-5 7
2-24 1-30
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TABLE VI.-Mean Clinical Value
No. of patients
Group C Group 4D
MCV at 3 months
Total MCV
All patients
Objective
responders only
All patients
Objective
responders only
4*0
7-5
42 0
75 0
5-7
8-9
61 -0
96*0
P<0-2
P<0 2
P<0*3
TABLE VII.-Success Rate
Intermediate
11
5
14
12
20
21
21
25
Failure
22
19
22
19
22
19
22
19
No. of patients evaluable
at time stated
49
50
49
50
46
47
44
45
patients in each group with involvement
at this site, but other visceral lesions were
less responsive.
Mean clinical value
The MCV at 3 months and the total
MCV averaged for each group are com-
pared in Table VI. Although all the
values were greater in Group 4D, the
difference was not statistically significant
with either ofthe two tests of significance
used.
Success rate
There were more successes at 3, 6 and
12 months in Group 4D (Table VII) but
this wasnotstatisticallysignificant (P<0O 1
at 3 months). At 24 months there was
only one success in each group.
Survival
This was similar for both groups of
patients (Fig). Analysis by the method
of Cox (1972) showed that the difference
in survival was not significant. After
correction for the slight initial disparity
in the involvement of different sites,
which favoured Group 4D, the two groups
are estimated to have had death rates in
the ratio 1-15 (for C) to 1 (for 4D); 95%
confidence limits for this ratio are 0-73
and 1-82. It is appropriate to note that
after relapse 12 patients in Group C then
received the 4 drug combination less cyclo-
phosphamide. In addition, some patients
in both groups received other treatments
on relapse, such as norethisterone acetate,
prednisone, adriamycin or radiotherapy
(Table VIII).
Modification to treatment due to toxicity
In Group C the cyclophosphamide
treatment was interrupted and/or the
dose reduced in 31 patients because of
leukopenia (20 patients), thrombocyto-
penia (1 patient), mouth ulcers (1 patient)
or nausea and vomiting (6 patients).
Four patients went on to intravenous
TABLE VIII.-Subsequent Therapy Re-
ceived by Patients after Failing or
Relapsing on the Trial
Norethisterone acetate
Prednisone
Hypophysectomy
Radiotherapy
4D less
cyclophosphamide
Adriamycin
No. of patients
A
Group C Group 4D
4 9
1 1
1 0
2 2
12
1 4
3 Months
6 Months
12 Months
24 Months
C
4D
C
4D
C
4D
C
4D
Success
16 (33%)
26 (52%)
13 (26%)
19 (38%)
4 (9%)
7 (15%)
1
1
733R. D. RUBENS, R. K. KNIGHT AND J. L. HAYWARD
SURVIVAL
O--*4D
0 6 12 18 24 30 36 42
Months
FiG. SSurvival curves calculatedl by the life-table methocl (- - - Group C; Group 4D).
cyclophosphamide because of intolerable
nausea and vomiting. In one patient
cyclophosphamide was withdrawn when
she developed severe non-thrombocyto-
penic purpura, although this was probably
the result of the administration of an
analgesic drug. One patient in Group C
developed irreversible marrow aplasia
and died from a septicaemia. Two pa-
tients had local radiotherapy to lesions
during chemotherapy.
In Group 4D the second or third intra-
venous doses in a course were occasionally
omitted in 15 patients because of leuko-
penia; this was a frequent occurence in
only 2 patients, one of whom eventually
continued treatment with cyclophos-
phamide only. Methotrexate was ulti-
mately omitted in one patient and 5-
fluorouracil in another because of mouth
ulcers, whilst in a further patient this
side-effect was controlled by a reduction
in the dose of 5-fluorouracil. In one
patient cyclophosphamide was withdrawn
after course 2 because of unacceptable
nausea and vomiting. In one patient
vincristine was substituted for vinblastine
and cyclophosphamide stopped after
course 5 in order to prevent further severe
leukopenia which had been responsible
0.
0. 0
'-4
$w4
*_1
0.
0.
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for a septicaemic episode. One patient
required the insertion of an A-V shunt
after the 4th course in order that the
intravenous drugs could be continued.
One patient in this grouphadasepticaemia
during a period of leukopenia but this
was treated successfully and chemotherapy
was resumed. Irreversible marrow
aplasia did not occur in any patient on
the 4-drug combination.
DISCUSSION
The valueofchemotherapyinadvanced
breast cancer is established and responders
to chemotherapy have been shown to have
a longer survival than non-responders
(Baker et al., 1974; Canellos et al., 1974a).
Many reports have suggested that multiple
drugs, in combination, given intermit-
tently are more effective than the agents
used singly (Broder and Tormey, 1974),
but this has not been shown unequivocally
in a clinical trial. In a small randomized
trial, 5-fluorouracil was shown to be as
effective as a 5-drug combination of 5-
fluorouracil, methotrexate, vincristine,
prednisone and chlorambucil, both with
regard to response rate and duration of
response (Lemkin and Dollinger, 1973).
The Eastern Co-Operative Oncology
Group has demonstrated clearly the su-
periority of a combination of cyclophos-
phamide, methotrexate and 5-fluorouracil
over L-phenylalanine mustard used singly
(Canellos et al., 1974b). However, the
response rate of 20% to L-phenylalanine
mustard in this trial was inferior to the
responses expected from any of the other
agentF iftheyhadbeenusedsingly (Carter,
1972), and so the trial did not prove that
combinations are superior to single agents.
Theresultsofthepresentstudysuggests
that a combination of cyclophosphamide,
methotrexate, 5-fluorouracil and vin-
blastine may result in a greater number
of responses, which last for a longer time
than cyclophosphamide alone although
the difference between the treatments
does not achieve formal significance.
Survival in the two groups was the
same but this was expected as other
treatments were available to relapsed
patients. Moreover, patients in Group C
who failed to respond were then given
combination chemotherapy. Administra-
tion of the 4-drug combination was easier
to control than continuous cyclophospha-
mide and it produced less toxicity,
particularly with regard to cystitis and
serious marrow suppression.
It would seem then that, although the
use of drug combinations probably repre-
sents an advance in the treatment of
breast cancer, this has not been proved in
the present trial. However, combination
chemotherapy is still in its infancy and
further improvements are likely. The
single most effective drug now in breast
cancer is adriamycin (Blum and Carter,
1974) and the use of this agent in com-
bination with other drugs may achieve a
greater degree of benefit (Brambilla,
DeLena and Bonadonna, 1974; DeLena
et al., 1975). The ultimate role of chemo-
therapy in breast cancer may be at an
earlier stage of the disease when the
eradication of all malignant cells might be
possible (Fisher et al., 1975).
We are grateful to Professor P. Armitage
for his advice in the analysis of these
results.
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